Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-200 vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Intravascular administration for angiocardiography, aortography, peripheral arteriography, venography, and contrast-enhanced computed tomography (CT),Body cavity imaging: arthrography, hysterosalpingography, and fistulography
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Iopamidol is not metabolized; eliminated unchanged via glomerular filtration.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
<2% bound; negligible binding to plasma proteins.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
0.24 L/kg; restricted to extracellular fluid, no intracellular penetration.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Oral: 0% (not absorbed); IV/IA/Intrathecal: 100% (administered directly into blood/CSF).
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
e GFR <30 m L/min/1.73m²: Administer with caution, consider prophylaxis with hydration and N-acetylcysteine. e GFR <15: Use only if diagnostic benefit outweighs risk of contrast-induced nephropathy. No specific dose reduction established; consider using lowest feasible volume.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No specific adjustments recommended for Child-Pugh class A, B, or C. Monitor renal function in patients with severe liver disease due to risk of hepatorenal syndrome.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Neonates and infants: 1.5-2.0 m L/kg intravenously. Children: 1.0-2.0 m L/kg intravenously; maximum 2.0 m L/kg. For intra-arterial use, consult weight-based dosing guidelines.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
No specific dose adjustment required based on age alone. Assess renal function (e GFR) in elderly patients as age-related decline is common; follow renal adjustment guidelines. Ensure adequate hydration before and after administration.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Not for intrathecal use with ISOVUE-200 (iopamidol injection 41%) due to risk of severe adverse reactions including seizures, paralysis, and death.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Risk of severe hypersensitivity reactions including anaphylaxis; acute kidney injury in patients with pre-existing renal impairment; CNS adverse effects including seizures with intrathecal administration; thyroid dysfunction in patients with hyperthyroidism; contrast-induced nephropathy.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Absolute: Hypersensitivity to iopamidol or any component; history of severe adverse reaction to iodinated contrast media; anuria or severe renal impairment (for intravascular use).,Relative: Pregnancy (only if clearly needed); lactation; multiple myeloma; pheochromocytoma; sickle cell disease.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
No specific food interactions with ISOVUE-200. Patients are generally encouraged to hydrate with clear fluids before and after the procedure. There are no dietary restrictions. However, in patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and only resumed after renal function is re-evaluated.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essential. Second and third trimesters: no known teratogenicity; neonatal thyroid function monitoring recommended after exposure.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Minimal excretion into breast milk; M/P ratio not established. Iodinated contrast is poorly absorbed orally and poses negligible risk to nursing infant. Interruption of breastfeeding not required.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No dose adjustment required in pregnancy; use lowest diagnostic dose. Monitor for volume overload in preeclampsia or compromised cardiac function.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
ISOVUE-200 (iopamidol 41%) is a nonionic, low-osmolality iodinated contrast medium. It is indicated for intrathecal administration in myelography (lumbar, thoracic, cervical, total columnar) and for contrast enhancement in CT and angiocardiography. Key pearls: (1) Monitor renal function before administration due to risk of contrast-induced nephropathy; (2) Prehydrate patients with normal saline to reduce nephrotoxicity; (3) Have emergency equipment available for hypersensitivity reactions; (4) Avoid in patients with known iodine allergy or prior reaction to contrast; (5) Do not mix with other medications in the same syringe; (6) For intrathecal use, ensure proper patient positioning to minimize cephalad flow; (7) Use with caution in patients with sickle cell disease, pheochromocytoma, or hyperthyroidism.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Inform your doctor if you have ever had an allergic reaction to iodine, contrast dye, or any medications.,Tell your healthcare provider if you have kidney disease, diabetes, asthma, heart disease, or thyroid problems.,You may need to stop taking certain medications (e.g., metformin) before the procedure; follow your doctor's instructions.,You will be asked to drink plenty of fluids before and after the procedure to protect your kidneys.,During injection, you may feel warmth, a metallic taste in the mouth, or nausea; these are usually temporary.,Report any severe symptoms such as difficulty breathing, hives, swelling, or chest pain immediately.,After the procedure, you may resume normal diet unless otherwise instructed.,Breastfeeding women should pump and discard breast milk for 24 hours after contrast administration.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-200 vs ANDROID 5, answered by our medical review team.
ISOVUE-200 is a Contrast Media that works by Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-200 and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-200 is: Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-200 and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-200 is classified as Category C. Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essen. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.